A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of VT-1161 in Healthy Japanese and Western Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2017
At a glance
- Drugs VT 1161 (Primary)
- Indications Onychomycosis; Vulvovaginal candidiasis
- Focus Adverse reactions; Pharmacokinetics
- 04 Jun 2017 Results from this trial presented at the American Society for Microbiology's ASM Microbe 2017 Conference, as reported by a Viamet Pharmaceuticals media release.
- 31 May 2017 New trial record
- 17 May 2017 According to a Viamet Pharmaceuticals media release, data from this trial will be presented at The American Society for Microbiologys ASM Microbe 2017 Conference.